Reoxygenation for Cyanotic Pediatric CHD
- Conditions
- Tetralogy of Fallot
- Interventions
- Procedure: Reoxygenation
- Registration Number
- NCT03568357
- Lead Sponsor
- Nanjing Medical University
- Brief Summary
Evidence is emerging that those patients with cyanotic pathologies may be more vulnerable to end-organ injury during and after surgery than those patients without, because of compromised cardiopulmonary performances or the proinflammatory state that follows conventional hyperoxic cardiopulmonary bypass.
Several clinical and basic studies have identified that controlled oxygenation during the initiation of bypass significantly improved the cardiac adaptation and remodeling capacity than hyperoxic oxygenation strategy among cyanotic patients undergoing tetralogy of Fallot repair, as evidenced by these reduced myocardial gene expression profiles associated with reoxygenation injury.
The investigators designed the reoxygenation for pediatric cardiac surgery study to investigate the effect of reoxygenation during cardiopulmonary bypass on clinical outcomes in patients with cyanotic congenital heart disease .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- The operation-naive infants and young children aged 1 months to 18 years old were eligible for enrolment if they were indicated for undergoing anticipated radical repair of cyanotic congenital heart disease with cardiopulmonary bypass.
- The chromosomal defects, airway and parenchymal lung disease, immunodeficiency, blood transfusion during the current admission, previous cardiac operation, or the opinion of the treating physician that randomization would not be in the best interest of the patient (lack of equipoise)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Reoxygenation Reoxygenation After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
- Primary Outcome Measures
Name Time Method Pediatric Logistic Organ Dysfunction (PELOD-2) score up to 30 days the change in the updated Pediatric Logistic Organ Dysfunction (PELOD-2) score (PELOD-2 score; range, 0 to 33 points, with higher scores indicating more severe organ dysfunction)
- Secondary Outcome Measures
Name Time Method low cardiac output syndrome up to 30 days Low cardiac output syndrome was defined as cardiac index \< 2.2 L/min/m2 of BSA with central venous pressure \>18 mmHg and mean arterial pressure \< 50 mmHg.
Trial Locations
- Locations (1)
TEDA International Cardiovascular Hospital
🇨🇳Tianjin, Tianjin, China